Literature DB >> 19546354

Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.

William D Meacham1, James W Antoon, Matthew E Burow, Amanda P Struckhoff, Barbara S Beckman.   

Abstract

An estimated 182,640 women and 1,990 men were diagnosed with breast cancer in 2008, and approximately 40,480 women and 450 men died from the disease. Thus, continued mechanistic studies are needed to understand the causes and develop additional therapeutics for this complicated disease. The MCF-7 cell system is one of the most recognized models for estrogen receptor (ER)-positive breast cancer and has generated approximately 13,000 publications cited in PubMed to date. A number of clues for biological mechanisms related to apoptotic/anti-apoptotic pathways and chemoresistance were elucidated and summarized in our previous review. The focus of this review is new knowledge of the central role of sphingolipid signaling in apoptotic mechanisms in estrogen receptor-positive breast cancer. The ultimate goal is to target crucial steps in survival signaling pathways that may ultimately provide additional translational solutions to the successful pharmacologic treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546354     DOI: 10.3181/0902-MR-77

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  10 in total

1.  Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Authors:  James W Antoon; Martin D White; William D Meacham; Evelyn M Slaughter; Shannon E Muir; Steven Elliott; Lyndsay V Rhodes; Hasina B Ashe; Thomas E Wiese; Charles D Smith; Matthew E Burow; Barbara S Beckman
Journal:  Endocrinology       Date:  2010-09-22       Impact factor: 4.736

2.  Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Carsten Denkert; Sibylle Loibl; Beyhan Ataseven; Toralf Reimer; Sven Becker; Uwe Holtrich; Achim Rody; Silvia Darb-Esfahani; Valentina Nekljudova; Gunter von Minckwitz
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-18       Impact factor: 4.553

3.  Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.

Authors:  Aparna Maiti; Kazuaki Takabe; Nitai C Hait
Journal:  Cell Signal       Date:  2017-01-17       Impact factor: 4.315

4.  Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Authors:  Vladimir Beljanski; Clayton S Lewis; Charles D Smith
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

5.  Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

Authors:  James W Antoon; Martin D White; Matthew E Burow; Barbara S Beckman
Journal:  Oncol Rep       Date:  2012-03-27       Impact factor: 3.906

6.  The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.

Authors:  Lyndsay V Rhodes; Ashley M Nitschke; H Chris Segar; Elizabeth C Martin; Jennifer L Driver; Steven Elliott; Seung Yoon Nam; Meng Li; Kenneth P Nephew; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Rep       Date:  2011-10-04       Impact factor: 3.906

7.  Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.

Authors:  James W Antoon; William D Meacham; Melyssa R Bratton; Evelyn M Slaughter; Lyndsay V Rhodes; Hasina B Ashe; Thomas E Wiese; Matthew E Burow; Barbara S Beckman
Journal:  J Mol Endocrinol       Date:  2011-04-28       Impact factor: 5.098

8.  Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.

Authors:  James W Antoon; Martin D White; Evelyn M Slaughter; Jennifer L Driver; Hafez S Khalili; Steven Elliott; Charles D Smith; Matthew E Burow; Barbara S Beckman
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

9.  Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Authors:  James W Antoon; Martin D White; Jennifer L Driver; Matthew E Burow; Barbara S Beckman
Journal:  Exp Biol Med (Maywood)       Date:  2012-08-02

10.  Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Authors:  James W Antoon; Rongye Lai; Amanda P Struckhoff; Ashley M Nitschke; Steven Elliott; Elizabeth C Martin; Lyndsay V Rhodes; Nam Seung Yoon; Virgilio A Salvo; Bin Shan; Barbara S Beckman; Kenneth P Nephew; Matthew E Burow
Journal:  Sci Rep       Date:  2012-07-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.